References
- US Food & Drug Administration. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims [Internet]. 2009 [cited 2022 Jun 22]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims.
- Rothrock NE, Kaiser KA, Cella D. Developing a valid patient-reported outcome measure. Clin Pharmacol Ther. 2011;90(5):737–742. doi: 10.1038/clpt.2011.195.
- Ahmed S, Barbera L, Bartlett SJ, et al. A catalyst for transforming health systems and person-centred care: Canadian national position statement on patient-reported outcomes. Curr Oncol. 2020;27(2):90–99. doi: 10.3747/co.27.6399.
- Dobrozsi S, Panepinto J. Patient-reported outcomes in clinical practice. Hematol Am Soc Hematol Educ Program. 2015;2015:501–506. doi: 10.1182/asheducation-2015.1.501.
- Mercieca-Bebber R, King MT, Calvert MJ, et al. The importance of patient-reported outcomes in clinical trials and strategies for future optimization. Patient Relat Outcome Meas. 2018;9:353–367. doi: 10.2147/PROM.S156279.
- Kitchen H, Rofail D, Caron M, et al. Oncology patient-reported claims: maximising the chance for success. Ecancermedicalscience. 2011;5:212.
- Kluetz PG, Slagle A, Papadopoulos EJ, et al. Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms. Clin Cancer Res. 2016;22(7):1553–1558. doi: 10.1158/1078-0432.CCR-15-2035.
- Committee for Medicinal Products for Human Use (CHMP). Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products [Internet]. 2005 [cited 2022 Jun 1]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulatory-guidance-use-healthrelated-quality-life-hrql-measures-evaluation_en.pdf.
- Coons SJ, Gwaltney CJ, Hays RD, et al. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO good research practices task force report. Value Health. 2009;12(4):419–429. doi: 10.1111/j.1524-4733.2008.00470.x.
- Erickson P, Willke R, Burke L. A concept taxonomy and an instrument hierarchy: tools for establishing and evaluating the conceptual framework of a patient-reported outcome (PRO) instrument as applied to product labeling claims. Value Health. 2009;12(8):1158–1167. doi: 10.1111/j.1524-4733.2009.00609.x.
- DeMuro C, Clark M, Mordin M, et al. Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and biologic license applications, 2006–2010. Value Health. 2012;15(3):443–448. doi: 10.1016/j.jval.2012.01.010.
- Basch E. Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels. Value Health. 2012;15(3):401–403. doi: 10.1016/j.jval.2012.03.1385.
- Kimmons R, West RE. Rapid academic writing: 4.1 introduction to literature reviews [Internet]. EdTech Books; 2018 [cited 2023 May 15]. Available from: https://edtechbooks.org/rapidwriting/lit_rev_intro#chapter-5-section-1
- Wolters Kluwer. Ovid is the world’s most trusted medical research platform [Internet]. 2022 [cited 2022 Jun 20]. Available from: https://www.wolterskluwer.com/en/solutions/ovid.
- U.S. Food and Drug Administration. Patient-Focused Drug Development: Collecting Comprehensive and Representative Input Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders [Internet]. 2020 [cited 2022 Aug 17]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-collecting-comprehensive-and-representative-input.
- Stiff PJ, Erder H, Bensinger WI, et al. Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant. 2006;37(4):393–401. doi: 10.1038/sj.bmt.1705250.
- Hellstrom WJG, Feldman R, Rosen RC, et al. Bother and distress associated with peyronie’s disease: validation of the Peyronie’s disease questionnaire. J Urol. 2013;190(2):627–634. doi: 10.1016/j.juro.2013.01.090.
- Coyne KS, Currie BM, Thompson CL, et al. Responsiveness of the Peyronie’s disease questionnaire (PDQ). J Sex Med. 2015;12(4):1072–1079. doi: 10.1111/jsm.12838.
- Patrick DL, Giuliano F, Ho KF, et al. The premature ejaculation profile: validation of self-reported outcome measures for research and practice. BJU Int. 2009;103(3):358–364. doi: 10.1111/j.1464-410X.2008.08041.x.
- Paty J, Turner-Bowker DM, Elash CA, et al. The VVSymQ instrument: use of a new patient-reported outcome measure for assessment of varicose vein symptoms. Phlebology. 2016;31(7):481–488. doi: 10.1177/0268355515595193.
- Osterhaus JT, Purcaru O, Richard L. Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA). Arthritis Res Ther. 2009;11(3):R73. doi: 10.1186/ar2702.
- Kepivance | European Medicines Agency [Internet]. [cited 2022 Aug 17]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/kepivance.
- Xiapex | European Medicines Agency [Internet]. [cited 2022 Aug 17]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/xiapex.
- DeMuro C, Clark M, Doward L, et al. Assessment of PRO label claims granted by the FDA as compared to the EMA (2006–2010). Value Health. 2013;16(8):1150–1155. doi: 10.1016/j.jval.2013.08.2293.
- Gnanasakthy A, Mordin M, Evans E, et al. A review of patient-reported outcome labeling in the United States (2011–2015). Value Health. 2017;20(3):420–429. doi: 10.1016/j.jval.2016.10.006.
- Gnanasakthy A, Norcross L, DeMuro Romano C, et al. A review of patient-reported outcome labeling of FDA-approved new drugs (2016–2020): counts, categories, and comprehensibility. Value Health. 2022;25(4):647–655. Available from: http://www.ncbi.nlm.nih.gov/pubmed/35365309.
- Gnanasakthy A, Mordin M, Clark M, et al. A review of patient-reported outcome labels in the United States: 2006 to 2010. Value Health. 2012;15(3):437–442. doi: 10.1016/j.jval.2011.11.032.
- Hong YD, Villalonga-Olives E, Perfetto EM. Patient-reported outcomes in orphan drug labels approved by the US food and drug administration. Value Health. 2019;22(8):925–930. doi: 10.1016/j.jval.2019.03.010.
- Lanar S, Acquadro C, Seaton J, et al. To what degree are orphan drugs patient-centered? A review of the current state of clinical research in rare diseases. Orphanet J Rare Dis. 2020;15(1):134. doi: 10.1186/s13023-020-01400-0.
- Slade A, Isa F, Kyte D, et al. Patient reported outcome measures in rare diseases: a narrative review. Orphanet J Rare Dis. 2018;13(1):9. doi: 10.1186/s13023-018-0810-x.